Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Semi-annual Business Results
December 6, 2004
- Top 28 Post 0.1% Decline in Non-consolidated Sales
December 6, 2004
- VITAL-NET: Profits Down Sharply Despite Growth in Sales
December 6, 2004
- Japan Should Boost Healthcare Spending to 9% of GDP: Mr Butler of PhRMA
December 6, 2004
- SSP: Sales of Rx Drugs Up 6.1% to \5.8 Bil.
December 6, 2004
- NEW PRODUCTS
December 6, 2004
- SSP to Concentrate on Consumer Healthcare: VP Yamashita
December 6, 2004
- Wyeth's Enbrel Receives Import Approval
December 6, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- OTC NEWS IN BRIEF
November 29, 2004
- Increased Demand Brings Good Performances to CMIC
November 29, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 29, 2004
- Cancer Treatment GLs in Preparation: JSCO
November 29, 2004
- NEW PRODUCTS
November 29, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 29, 2004
- REGULATORY NEWS IN BRIEF
November 29, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…